Bioinformatics Research Tools: From Data Flood to Intelligent Interpretation

If there is one thing that has grown "exponentially" in biological research over the past decades, it must be data. In 1982, when GenBank was first established, it contained only 606 sequences, totaling approximately 680,000 base pairs. According to the official NCBI release, GenBank Release 269.0 (December 16, 2025) now contains 6.03 billion sequence records, with a total of 49.73 trillion bases.

The history of bioinformatics research tools is, in essence, a story of humanity's relentless pursuit to process astronomical amounts of data. With each wave of data growth, a new generation of tools has emerged, striving to keep pace. However, beneath this narrative of "data explosion" and "tool prosperity," a deeper structural issue is gradually surfacing.

Codex Vault of Unwritten Genes

I. The Data Flood and the Limits of Traditional Tools

Biology is no longer a discipline where groundbreaking discoveries can be made with just a pipette and a petri dish. High-throughput sequencing technologies now allow a single instrument to produce tens of gigabytes to terabytes of data daily, and the total data accumulated by research institutions worldwide has long since crossed the petabyte threshold.

Take the protein universe, for instance. By February 2024, the UniProt database contained over 240 million protein sequences. However, the proportion of sequences that have been experimentally validated and manually curated—those housed in the Swiss-Prot section—is less than 0.3% of the total. The vast majority, the TrEMBL section, rely on automated computational annotation. This means that the number of proteins whose functions have been characterized through experimental methods is merely a tiny fraction of the known sequences—leaving the functions of most proteins a mystery. This predicament of "sequence known, function unknown" is the very driving force behind the continuous iteration of tools for protein function prediction.

Faced with such massive data volumes, traditional tools are reaching their limits. Early sequence alignment tools like BLAST are designed to retrieve homologous sequences. The subsequent step of functional annotation often relies on a common assumption—"similar sequences often have similar functions". When this logic encounters an "orphan protein" with no known homolog, it simply breaks down, leaving traditional methods helpless. A more insidious challenge lies in the coordination between tools. A typical bioinformatics workflow requires stitching together several independent tools, manually handling data format conversions, and constantly switching between different platforms. Time is spent not on analysis, but on making these tools "talk" to each other.

At the 798th Xiangshan Science Conference held in November 2025, Academician Chen Runsheng of the Chinese Academy of Sciences pointed out that the complexity of current biological data far exceeds the scope of traditional gene sequences, covering multi-layered information from transcriptomes, proteomes, and metabolomes. He also affirmed the potential of AI—not only can it autonomously learn patterns from massive datasets without relying on pre-set prior knowledge, but it also possesses the ability to "generate new knowledge" based on the rules it has learned. This is the core driving force behind the evolution of bioinformatics research tools: a shift from "manual mining" to "intelligent interpretation", and from "tool user" to "AI collaborator."

However, the path to "intelligent interpretation" is paved with new challenges brought by the increasing complexity of the tools themselves.

II. The Dilemma of Tools: A Thriving Ecosystem with Limited Accessibility

In the field of bioinformatics, the tool ecosystem is both highly prosperous and highly complex. From sequence alignment to structure prediction, from gene annotation to functional analysis, there are multiple tools to choose from for every subtopic.

For protein function prediction, the evolution of traditional computational methods is clear. Early homology-based methods solved the problem of annotating functions for proteins with known homologs. With the arrival of machine learning, algorithms like support vector machines and random forests began demonstrating considerable predictive power on specific datasets. The latest research frontier is the application of protein language models for function prediction. A 2025 review concluded that protein language models, which can leverage massive sequence data to mine deep semantic information, have shown significant advantages in the accuracy and depth of functional prediction.

Yet, a new contradiction is emerging: a tool's "power" does not always correlate with its "usability." Dependence on computational tools has shifted from "optional" to "essential," but the barriers to installation, configuration, and operation remain high. Consequently, bioinformatics researchers today often find themselves in an awkward position: they have many tools at their disposal, but few that they can actually use effectively. Among academics, the evaluation criteria for these tools are shifting from "how powerful it is" to "how easy it is to use."

"Platformization" has become a key direction in the evolution of bioinformatics tools. Compared to traditional locally installed tools, platform-based solutions eliminate the need for software installation, environment configuration, parameter tuning, and resource management, significantly lowering the barrier to entry. In multi-omics data integration scenarios, the integration capabilities of platforms are demonstrating irreplaceable value. In 2025, a research team developed a multi-agent framework called BioMaster, specifically designed to automate and streamline complex bioinformatics workflows, showcasing the potential of platformization in solving tool coordination problems.

Dialogue Between Hand & Algorithm

III. New Challenges for AI Tools: The Cost of Trust and Technical Debt

With the explosion of generative AI and large language models (LLMs), AI-assisted bioinformatics tools are rapidly gaining popularity. However, there is another side to the coin. While AI is fast, the cost of verification—ensuring its output is accurate for rigorous bioinformatics analysis—could negate the time savings. AI tends to generate code that "just works," but which can easily accumulate "technical debt" over time. Furthermore, code generated by AI lacks the depth of memory that a researcher would have built by writing it line by line, making it difficult to maintain in the long run.

In March 2025, a benchmark called BixBench provided some concrete numbers. The test involved 53 real-world bioinformatics scenarios, covering 12 core tasks including RNA-seq and single-cell sequencing, using a dual "open-answer" and "multiple-choice" evaluation system. The results showed a notable duality. In the strict open-answer regime, where the model had to generate a complete analysis plan autonomously, GPT-4o's accuracy was a mere 9%, and Claude 3.5 Sonnet only 17%. When switched to a multiple-choice format, after allowing the model to select "abstain," the two models' accuracies rose to 22% and 24% respectively. If forced to choose without "abstain," their scores could be further increased to 31% and 34%. Yet, even under these conditions, their performance fell far short of expectations for a human expert. The research team identified three critical weaknesses: a high error rate (up to 83%) in multi-step data analysis, extremely low accuracy in interpreting heatmaps and PCA plots, and a logical error rate in hypothesis testing reaching as high as 92%. This data clearly indicates that although the application of AI in bioinformatics is an unstoppable trend, there is still a long way to go before it achieves genuinely reliable, "expert-level" assistance.

IV. Platformization and Agents: The Next Stage for Bioinformatics Tools

Globally, the market for AI in scientific discovery is growing rapidly. According to QYResearch, the global AI for Science market was valued at approximately $4.538 billion in 2025 and is projected to reach $26.23 billion by 2032, with a compound annual growth rate (CAGR) of 28.9%. Driven by these numbers is a shared expectation from both academia and industry for "intelligent research tools."

In bioinformatics, multi-agent collaboration frameworks are becoming a new solution for complex analysis workflows. Systems like BioMaster, which deploy multiple specialized agents to work in parallel, are replacing manual, step-by-step workflows for tasks like RNA-seq analysis. This allows researchers to focus on higher-level scientific questions rather than software operations. From a broader perspective, it's an engineering practice that embodies the philosophy of "letting scientists get back to the science itself."

For Tianwu Technology, its platformization experience in protein engineering also offers valuable insights for broader bioinformatics tools. Its independently developed MatwingsVenus™ platform demonstrates an integrated model of "conversational interaction and full-process coverage" in protein design—users simply state their task goals in natural language, and the platform automatically handles in-depth research, database retrieval, protein design, and a series of complex R&D tasks. This design concept of encapsulating professional tools behind an intelligent agent could potentially be extended from protein engineering to a wider range of bioinformatics tasks in the future.

The Platform of Integrated Algorithms

V. Returning to the Scientific Question Itself

Looking back at the evolution of bioinformatics research tools, from single-function to integrated platforms, from command-line to natural language interaction, from "humans learning tools" to "tools learning humans"—each leap has reduced the cognitive load on researchers.

But the real challenge is not whether the tools are powerful enough, but whether researchers are losing their "sense" of the underlying principles as tools become increasingly powerful. There is no single answer to this question. Optimists argue that tools free up human resources, allowing scientists to step back from tedious data processing and focus on higher-order creative work. Pessimists worry that as "black box" tools become more common, the next generation of researchers may lack an intuitive understanding of the full "data-to-conclusion" chain, leaving them helpless when faced with anomalous results that tools cannot handle.

Regardless of which view one holds, one direction is clear. The ultimate goal of bioinformatics research tools is never to replace scientists, but to allow scientists to dedicate their energy to the scientific question itself—to hypothesize, to design, to reason.

Data will continue to accumulate, tools will continue to emerge, but the ability to ask a good question will always be the true starting point of scientific progress.